Don’t Wait for the Patent Cliff: Build Pharmaceutical Supply Chain Resilience Years Before Drug Patent Expiration
Every procurement director who has watched a blockbuster drug lose market exclusivity knows the same thing in hindsight: the scramble
May 2026
Win the 180-Day FDA Exclusivity Race: Legal, Regulatory, and Commercial Playbook
The 180-day generic drug exclusivity period is, by raw financial math, one of the most lucrative regulatory prizes in the
Win the 180-Day FDA Exclusivity Race: Legal, Regulatory, and Commercial Playbook Read Post »
The PBM Endgame: What Mark Cuban Got Right (and Pharma Is Still Ignoring)
Mark Cuban launched Cost Plus Drugs in January 2022 with a simple premise: buy generic drugs at manufacturer cost, add
The PBM Endgame: What Mark Cuban Got Right (and Pharma Is Still Ignoring) Read Post »
Mark Cuban’s Cost Plus Drugs Is Killing Spread Pricing — Here’s What That Actually Means
A billionaire’s drugstore startup exposed the $6 billion arbitrage game inside America’s pharmacy benefit system. Now the entire supply chain
Mark Cuban’s Cost Plus Drugs Is Killing Spread Pricing — Here’s What That Actually Means Read Post »
Why Cuban’s Cost Plus Drugs Works for Generics—But Brand Drugs Are a Different Fight Entirely
Mark Cuban built his fortune by spotting inefficient markets and charging in with a simpler model. The Dallas Mavericks. HDNet.
How Cost Plus Drugs Exposes Drug Pricing Secrets Your Competitors Don’t Want You to Know
In January 2022, Mark Cuban launched a pharmacy that listed drug prices on a public website. That alone was unusual.
How Cost Plus Drugs Exposes Drug Pricing Secrets Your Competitors Don’t Want You to Know Read Post »
Mark Cuban’s Generic Drug Play: Who Gets Disrupted First?
Mark Cuban built a $5.8 billion fortune buying and selling assets that others undervalued. In January 2022, he turned that
Mark Cuban’s Generic Drug Play: Who Gets Disrupted First? Read Post »
Patent Deals Predict Biotech Hiring: How to Read Licensing Signals Before the Jobs Post
The press release drops at 7 a.m. Eastern. A mid-cap biotech has just signed a license agreement with a major
Patent Deals Predict Biotech Hiring: How to Read Licensing Signals Before the Jobs Post Read Post »
Drug Patent Expirations for the Week of April 26, 2026
CABENUVA KIT (cabotegravir; rilpivirine) Viiv hlthcare Patent: 10,927,129 Expiration: Apr 28, 2026 See More … For more information on how
Drug Patent Expirations for the Week of April 26, 2026 Read Post »
